VYNDAMAX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYNDAMAX (VYNDAMAX).
Tafamidis binds to transthyretin (TTR), stabilizing the tetrameric form and inhibiting dissociation into monomers, which are prone to amyloid fibril formation. This prevents amyloid deposition in tissues.
| Metabolism | Primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A9; minor CYP3A4 involvement. |
| Excretion | Primarily excreted unchanged in feces (87% of administered dose) via biliary secretion; renal excretion is minimal (<1% unchanged in urine). |
| Half-life | Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing and achieving steady state within 2 weeks. |
| Protein binding | Highly bound to plasma proteins, predominantly albumin (99.7% bound). |
| Volume of Distribution | Apparent volume of distribution is approximately 18 L (0.2-0.3 L/kg), indicating limited distribution into tissues. |
| Bioavailability | Absolute oral bioavailability is approximately 60-70% under fasting conditions; absorption is reduced by high-fat meals. |
| Onset of Action | Oral: Clinical effect onset is gradual; reduction in transthyretin stabilization occurs within days, but symptomatic benefit may take weeks to months. |
| Duration of Action | Duration of action is sustained with daily dosing due to long half-life; continuous stabilization of TTR tetramers is maintained throughout the dosing interval. |
| Molecular Weight | 398.5 |
61 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min) or dialysis; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Not indicated in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; geriatric patients (≥65 years) have been included in clinical trials with similar safety and efficacy as younger adults. |
| 1st trimester | No adequate human data; animal studies show embryofetal toxicity (cardiac malformations, reduced fetal weight) at exposures below human AUC. Avoid use in first trimester unless benefit outweighs risk. |
| 2nd trimester | Potential fetal harm based on mechanism (TTR stabilizer, may disrupt thyroxine transport). Limited human data; animal studies show adverse effects. Use only if clearly needed. |
| 3rd trimester | Same risks as second trimester. May cause fetal hypothyroidism or neurological deficits. Avoid use in third trimester unless essential. |
Clinical note
Comprehensive clinical and safety monograph for VYNDAMAX (VYNDAMAX).
| Placental transfer | Likely crosses placenta due to lipophilicity and molecular weight <600 Da; animal studies confirm fetal exposure. Human data not available, but transfer is expected. |
| Breastfeeding | No data on presence in human milk; based on molecular weight (398.5 Da) and high protein binding, excretion is likely low but not negligible. Potential for serious adverse effects in the infant (e.g., thyroid dysfunction). Consider benefits of breastfeeding vs risk of drug exposure. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to tafamidis or any excipient
| Precautions | Not recommended for use in patients with NYHA Class IV heart failure due to lack of efficacy data., Monitor for hepatotoxicity; liver function tests should be performed periodically., Risk of volume depletion; ensure adequate hydration. |
| Food/Dietary | Grapefruit juice may increase tafamidis exposure; avoid concomitant intake. No other significant food interactions identified. Tafamidis can be taken with or without food. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, tafamidis administration to pregnant rabbits during organogenesis resulted in developmental toxicity, including increased embryofetal mortality and decreased fetal body weight, at doses producing maternal exposures approximately 39 times the human exposure at the recommended human dose of 61 mg. Based on its mechanism of action, tafamidis may cause fetal harm when administered to a pregnant woman. Tafamidis is a transthyretin stabilizer; transthyretin is involved in thyroxine transport. Disruption of maternal thyroxine levels during pregnancy may affect fetal neurodevelopment. Therefore, tafamidis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no information on the risk of miscarriage or malformations in humans. |
| Fetal Monitoring | Monitor pregnant women exposed to tafamidis for signs of fetal distress, including assessment of fetal growth and well-being via ultrasound, amniotic fluid volume, and non-stress testing as clinically indicated. Monitor maternal thyroid function (TSH, free T4) regularly throughout pregnancy, as tafamidis may alter thyroid hormone levels due to thyroxine displacement from transthyretin. Assess for symptoms of hypothyroidism and adjust levothyroxine dose if needed. Monitor liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine, BUN) periodically due to potential for hepatic and renal impairment. In infants, monitor for signs of hypothyroidism and neurodevelopmental outcomes. |
| Fertility Effects | Based on animal studies, tafamidis may impair male fertility. In male rats, tafamidis administration resulted in reduced fertility and sperm count at exposures approximately 21 times the human exposure. No significant effects on female fertility were observed in animal studies. There are no human data on fertility effects. It is unknown whether tafamidis affects human fertility. |
| VYNDAMAX (tafamidis) is a transthyretin stabilizer indicated for transthyretin-mediated amyloidosis (ATTR) in adults with cardiomyopathy. Monitor for heart failure exacerbation, arrhythmias, and fluid overload. Renal dose adjustment not required; hepatic impairment may increase exposure. Contraindicated in patients with hypersensitivity to tafamidis or any excipient. Drug interactions include CYP3A4 inducers (e.g., rifampin) and inhibitors (e.g., ketoconazole) which may alter tafamidis levels. Baseline and periodic monitoring of cardiac biomarkers (NT-proBNP, troponin), echocardiography, and clinical status is recommended. |
| Patient Advice | Take VYNDAMAX exactly as prescribed, usually once daily with or without food. · Do not crush, chew, or break the capsules; swallow whole. · Report any new or worsening shortness of breath, swelling in the legs, rapid weight gain, palpitations, or lightheadedness immediately. · Avoid grapefruit juice as it may increase tafamidis levels. · Inform all healthcare providers about your VYNDAMAX use, especially before any surgery or procedure. · Pregnancy: use effective contraception; notify your doctor if you become pregnant or plan to breastfeed. · Store at room temperature away from moisture and heat. |